Bookmarks
Incidence and prevalence of heart failure in patients with idiopathic pulmonary fibrosis (IPF) between 2010 - 2019 and the impact of heart failure treatment on IPF mortality: a population-based study using CPRD Aurum
Safe People
Imperial College London
Academic Institute
Jennifer Quint - Chief Investigator - Imperial College LondonArdita Koteci - Corresponding Applicant - Imperial College LondonAnn Morgan - Collaborator - Imperial College LondonHannah Whittaker - Collaborator - Imperial College LondonLaura Portas - Collaborator - Imperial College LondonPeter George - Collaborator - Royal Brompton Hospital
Safe Projects
CPRD870
Idiopathic pulmonary fibrosis (IPF) is a chronic condition of unknown cause resulting in scarring of the lungs. It is more common in men, with older age and smoking being additional risk factors. Currently, there are no treatments available that can cure the disease, only medications that can slow the rate of scarring. IPF has a very poor prognosis, with the average patient surviving only 3-4 years post diagnosis, an outlook which is worse than several cancers.
Idiopathic pulmonary fibrosis (IPF) is a progressive lung condition of unknown aetiology, resulting in irreversible lung scarring. Multimorbidity is common in IPF and a risk factor for reduced survival. In particular, cardiovascular diseases are the most prevalent comorbidity and significant risk factors for increased mortality.
27/01/2021
Safe Data
HES Admitted Patient Care
ONS Death Registration Data
Patient Level Index of Multiple Deprivation
Safe Setting
Release